MoneyWorks4Me

Glenmark Pharmaceuticals informs about media release

09 Jun 2025 Evaluate
Glenmark Pharmaceuticals has informed that it attached media release titled ‘Glenmark Pharmaceuticals to Launch DCGI-approved BRUKINSA® in India to Advance Treatment of Hematological Malignancies’.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma. Share Price

2289.45 2.45 (0.11%)
10-Aug-2026 09:20 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1961.05
Dr. Reddys Labs. 1175.75
Cipla 1479.75
Lupin 2325.15
Zydus Lifesciences 1119.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: